Estimated cardiac risk associated with macrolides and fluoroquinolones decreases substantially when adjusting for patient characteristics and comorbidities

Journal of the American Heart Association

Volumn 7, Issue 9, 2018, Pages

  Polgreen, Linnea A ^a   Riedle, Benjamin N ^a   Cavanaugh, Joseph E ^a   Girotra, Saket ^b   London, Barry ^b   Schroeder, Mary C ^a   Polgreen, Philip M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Cardiac; Medication; Morbidity; Mortality

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CLARITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH INSURANCE; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MEDICAL PROCEDURES; MEDICARE; MORTALITY; PATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; VERY ELDERLY; CLINICAL DECISION MAKING; HEALTH STATUS; HEART INFARCTION; PROGNOSIS; RISK FACTOR; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ARRHYTHMIAS, CARDIAC; CLINICAL DECISION-MAKING; COMORBIDITY; FEMALE; FLUOROQUINOLONES; HEALTH STATUS; HUMANS; MACROLIDES; MALE; MEDICARE; MYOCARDIAL INFARCTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 85046413903     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.117.008074     Document Type: Article

References (26)

1. Vogt AW, Zollo RA. Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation. Anest Analg. 1997;85:1011-1013.
2. Arellano-Rodrigo E, Garcia A, Mont L, Roque M. Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome. Med Clin. 2001;117:118-119.
3. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J. 2003;116:U666.
4. Koh TW. Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. Pacing Clin Electrophysiol. 2001;24:1575-1576.
5. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed. 2006;77:30-32.
6. Huang B-H, Wu C-H, Hsia C-P, Chen CY. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007;30:1579-1582.
7. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol. 2007;18:243-246.
8. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881-1890.
9. Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, Jacob S, Strayer SM. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014;12:121-127.
10. Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368:1704-1712.
11. Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis. 2012;55:1457-1465.
12. Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, Johnson CS, Alvarez CA, Frei CR, Good C, Restrepo MI, Downs JR, Anzueto A. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014;311:2199-2208.
13. Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and beta-lactam/beta-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis. 2015;60:566-577.
14. Trac MH, McArthur E, Jandoc R, Dixon SN, Nash DM, Hackam DG, Garg AX. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. Can Med Assoc J. 2016;188:E120-E129.
15. Trifiro G, de Ridder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, Mazzaglia G, Bezemer I, Garbe E, Schink T, Poluzzi E, Froslev T, Molokhia M, Diemberger I, Sturkenboom M. Use of azithromycin and risk of ventricular arrhythmia. CMAJ. 2017;189:E560-E568.
16. Foster ED, Cavanaugh JE, Haynes WG, Yang M, Gerke AK, Tang F, Polgreen PM. Acute myocardial infarctions, strokes and influenza: seasonal and pandemic effects. Epidemiol Infect. 2013;141:735-744.
17. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics. 2001;57:120-125.
18. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care. 2005;10:R8.
19. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45:158-165.
20. Perry TW, Pugh MJ, Waterer GW, Nakashima B, Orihuela CJ, Copeland LA, Restrepo MI, Anzueto A, Mortensen EM. Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med. 2011;124:244-251.
21. Aliberti S, Ramirez J, Cosentini R, Valenti V, Voza A, Rossi P, Stolz D, Legnani D, Pesci A, Richeldi L, Peyrani P, Massari FM, Blasi F. Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia. ERJ Open Res. 2015;1:00020-2015.
22. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302:758-766.
23. Pearce DC, McCaw JM, McVernon J, Mathews JD. Influenza as a trigger for cardiovascular disease: an investigation of serotype, subtype and geographic location. Environ Res. 2017;156:688-696.
24. MacDonald MI, Shafuddin E, King PT, Chang CL, Bardin PG, Hancox RJ. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4:138-148.
25. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290:1459-1466.
26. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637-1645.